Enteric Disease Testing Has Been Significantly Used For Ensuring Food Safety Protocols
Enteric
disease testing is a vital part of preventive care for people suffering from
diarrhea. It helps prevent the spread of infections by identifying the cause of
the disease and identifying possible treatment options. It also helps detect
the presence of infectious agents, including viruses and parasites. Using rapid
tests, doctors can detect the presence of bacteria and other pathogens that
cause diarrhea and hemolytic uremic syndrome in food, water, and environmental
samples.
The
Global
Enteric Disease Testing Market is estimated to account for US$ 4,432.7 Mn in terms of value by the
end of 2027.
Traditionally,
the diagnosis of enteric disease testing has relied on culture-confirmed
infections in feces. This approach has yielded nearly all of the information we
know about the disease. However, the trend in enteric disease testing is
towards rapid nonculture techniques. It is important to ensure that these
rapid, nonculture tests are consistently performed. In regions such as the
United States, the increasing developments by labs and pharmaceuticals have
increased the usage of enteric disease testing. For instance, in February 2021,
Mesa Biotech was acquired by Thermo Fisher Scientific, Inc.
The
public health units perform enteric disease testing on stool specimens, and
these cultures are used to identify diseases caused by bacteria, viruses, or
parasites. These tests are used to diagnose and treat patients, and they can be
used by both community physicians and hospitals. The common pathogens tested in
routine stool cultures include Shigella, E. coli O157:H7, and Campylobacter.
Vibrio cultures are also available upon request.
There
are companies focused on the development of innovative products and services
that improve the healthcare industry's patient care. In addition, they are
focusing on mergers and acquisitions to further expand their global presence.
Technological advancements have impacted the requirements for enteric disease
testing. In particular, the industry has been looking for ways to cut down on
lead times, increase sample utilization, and reduce the overall costs of
testing.
Comments
Post a Comment